Showing results (221-230 of 253) with videos related to

Sort By:
Pageof 26
American Journal of Hematology|May 14, 2025
Total Metabolic Tumor Volume Is a Strong Independent Prognostic Factor in Follicular Lymphomas: Results From a Sub-Study of the FOLL12 TrialRexhep Durmo, Stephane Chauvie, Carla Minoia, et al.
Advances in Hematology|February 7, 2022
Safety and Efficacy of Subcutaneous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Results from an Italian Phase IIIb StudyMario Petrini, Gianluca Gaidano, Andrea Mengarelli, et al.
Blood Cancer Journal|August 21, 2024
Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trialGianluca Cavallaro, Anna Grassi, Chiara Pavoni, et al.
Leukemia|March 8, 2024
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE studyAnnalisa Chiappella, Beatrice Casadei, Patrizia Chiusolo, et al.
Haematologica|August 29, 2020
Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06Chiara Caprioli, Federico Lussana, Silvia Salmoiraghi, et al.
Leukemia|January 18, 2023
Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II studyAnnalisa Chiappella, Anna Dodero, Andrea Evangelista, et al.
The Lancet. Oncology|October 3, 2015
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trialAlessandro Rambaldi, Anna Grassi, Arianna Masciulli, et al.
The Lancet. Oncology|January 10, 2026
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trialHermann Einsele, Jesús San-Miguel, Binod Dhakal, et al.
The Lancet. Oncology|September 13, 2021
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 studyStephen J Schuster, Constantine S Tam, Peter Borchmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2017
Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell LymphomasSergio Cortelazzo, Corrado Tarella, Alessandro Massimo Gianni, et al.
Pageof 26